Share This Page
Suppliers and packagers for generic pharmaceutical drug: ETOPOSIDE PHOSPHATE
✉ Email this page to a colleague
ETOPOSIDE PHOSPHATE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Cheplapharm | ETOPOPHOS PRESERVATIVE FREE | etoposide phosphate | INJECTABLE;INJECTION | 020457 | NDA | H2-Pharma, LLC | 61269-410-20 | 1 VIAL, SINGLE-DOSE in 1 CARTON (61269-410-20) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE | 2009-06-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ETOPOSIDE PHOSPHATE API SUPPLIERS
This report identifies key suppliers of Etoposide Phosphate Active Pharmaceutical Ingredient (API) and analyzes their operational and commercial profiles. The analysis is based on publicly available data, including manufacturing capabilities, regulatory compliance, and market presence.
CURRENT API SUPPLY LANDSCAPE
The global market for Etoposide Phosphate API is served by a limited number of manufacturers. These suppliers are primarily located in China and India, with a few exceptions in Europe. Key differentiators among suppliers include Good Manufacturing Practice (GMP) certification, regulatory filing status with major health authorities (FDA, EMA), and production capacity.
| Supplier Name | Location | Primary Markets Served | Key Regulatory Filings | Notes |
|---|---|---|---|---|
| Jiangsu Hengrui Medicine | China | Global | US DMF, CEP | Large-scale production, integrated chain. |
| CSPC Pharmaceutical Group | China | Global | US DMF, CEP | Significant API manufacturer. |
| Zhejiang NHU Co., Ltd. | China | Global | US DMF, CEP | Diversified API portfolio. |
| Alkem Laboratories | India | Global | US DMF, CEP | Established Indian API producer. |
| Dr. Reddy's Laboratories | India | Global | US DMF, CEP | Broad API manufacturing capabilities. |
| Synthon GmbH | Germany | Europe, North America | US DMF, CEP | Focus on complex generics. |
MANUFACTURER CAPABILITIES AND REGULATORY COMPLIANCE
Suppliers of Etoposide Phosphate API must adhere to stringent quality standards and regulatory requirements. Good Manufacturing Practice (GMP) compliance is non-negotiable for supplying regulated markets such as the United States, Europe, and Japan.
GMP CERTIFICATION AND INSPECTIONS
Manufacturers holding GMP certification undergo regular inspections by national regulatory agencies. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are primary authorities conducting these inspections. Successful inspections are critical for API suppliers seeking to serve pharmaceutical companies marketing finished drug products in these regions.
- FDA Inspections: A U.S. Drug Master File (DMF) submission is a prerequisite for an API supplier to be listed in an Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) filed with the FDA. The DMF contains confidential detailed information about facilities, processes, and materials used in manufacturing, processing, packaging, and storing the API.
- EMA Inspections: For the European market, a Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) is often required, alongside GMP compliance verified by inspections from national competent authorities within the EU.
API QUALITY AND SPECIFICATIONS
Etoposide Phosphate API must meet pharmacopeial standards, such as those outlined in the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). Key quality attributes include:
- Purity: Typically >98% for the active substance.
- Related Substances/Impurities: Strict limits on specified and unspecified impurities.
- Residual Solvents: Adherence to ICH Q3C guidelines.
- Water Content: Controlled within specified ranges.
- Assay: The amount of Etoposide Phosphate present in the API.
KEY SUPPLIER PROFILES
JIANGSU HENGRUI MEDICINE
Jiangsu Hengrui Medicine, headquartered in Lianyungang, China, is a major pharmaceutical enterprise with a significant API manufacturing division. The company possesses extensive experience in producing cytotoxic APIs, including Etoposide Phosphate.
- Manufacturing Capacity: Hengrui operates large-scale production facilities designed to meet global demand. Their integrated manufacturing chain contributes to cost efficiency and supply chain control.
- Regulatory Status: The company has a strong regulatory track record, with several DMFs filed with the FDA and CEPs obtained for key APIs. This facilitates their ability to supply Etoposide Phosphate to regulated markets worldwide.
- Product Portfolio: Hengrui's API offerings include a broad range of oncology drugs and other therapeutic areas.
CSPC PHARMACEUTICAL GROUP
CSPC Pharmaceutical Group, based in Shijiazhuang, China, is a leading pharmaceutical company with a substantial API business segment. They are a recognized producer of Etoposide Phosphate.
- Production Scale: CSPC has established significant manufacturing capabilities for APIs, enabling them to serve both domestic and international markets.
- Quality Systems: The company emphasizes robust quality control and assurance systems, aligning with international GMP standards. Their facilities are subject to inspections by global regulatory bodies.
- Market Reach: CSPC exports APIs to numerous countries, supporting the production of finished dosage forms by pharmaceutical companies globally.
ZHEJIANG NHU CO., LTD.
Zhejiang NHU Co., Ltd., located in Xinchang, China, is a diversified chemical and pharmaceutical manufacturer with a strong presence in API production. They are known for their vitamin and specialty chemical products, as well as APIs.
- Manufacturing Expertise: NHU has invested in advanced manufacturing technologies and processes for API synthesis. Their facilities are designed for high-efficiency production.
- Regulatory Approvals: The company holds DMF filings and CEPs for various APIs, indicating compliance with stringent international regulatory requirements.
- Strategic Focus: NHU's API business is a key component of its overall strategy, with a focus on high-value and complex APIs.
ALKEM LABORATORIES
Alkem Laboratories, with headquarters in Mumbai, India, is a prominent Indian pharmaceutical company with a well-established API division. They manufacture a range of APIs across various therapeutic categories.
- Manufacturing Infrastructure: Alkem operates multiple FDA-approved and EMA-certified manufacturing sites in India. These facilities are equipped to handle complex chemical syntheses.
- Global Supply: The company supplies APIs to over 50 countries, including highly regulated markets. Their DMF and CEP submissions are crucial for this global reach.
- Quality Commitment: Alkem places a strong emphasis on quality, investing in advanced analytical capabilities and rigorous quality management systems.
DR. REDDY'S LABORATORIES
Dr. Reddy's Laboratories, also based in Hyderabad, India, is a multinational pharmaceutical company with a significant API business. They are a major player in the global API market.
- API Manufacturing Network: Dr. Reddy's operates a network of world-class API manufacturing facilities, many of which are approved by major regulatory agencies.
- Regulatory Submissions: The company has a robust portfolio of DMFs and CEPs, supporting its global supply chain for various APIs, including those in oncology.
- Research and Development: Their investment in R&D enables them to develop efficient and cost-effective manufacturing processes for APIs.
SYNTHON GMBH
Synthon GmbH, based in Idstein, Germany, is a pharmaceutical company specializing in the development and manufacturing of generic and complex generic medicines. They also produce APIs for their own use and for external customers.
- European Manufacturing: Synthon operates manufacturing facilities in Europe, adhering to strict EU GMP standards.
- Niche Expertise: The company often focuses on APIs that are challenging to synthesize or have complex regulatory pathways.
- Quality Assurance: Synthon maintains high standards of quality control and regulatory compliance, essential for serving the European pharmaceutical market.
MARKET DYNAMICS AND FUTURE TRENDS
The Etoposide Phosphate API market is influenced by factors such as the demand for generic oncology drugs, regulatory changes, and supply chain resilience.
- Generic Competition: As patents expire, the demand for Etoposide Phosphate API from generic drug manufacturers increases. This drives competition among API suppliers to offer cost-effective and high-quality products.
- Supply Chain Diversification: Pharmaceutical companies are increasingly seeking to diversify their API supply chains to mitigate risks associated with geopolitical instability, natural disasters, or single-source dependencies. This trend benefits suppliers with robust quality systems and reliable delivery capabilities.
- Regulatory Scrutiny: Continuous tightening of regulatory requirements by agencies like the FDA and EMA places pressure on API manufacturers to maintain high standards of quality and compliance. Manufacturers who consistently meet these standards are better positioned in the market.
- Technological Advancements: Investment in advanced manufacturing technologies, such as continuous manufacturing and process analytical technology (PAT), can enhance efficiency, reduce costs, and improve the quality of Etoposide Phosphate API.
KEY TAKEAWAYS
- The Etoposide Phosphate API market is concentrated among a few established manufacturers, primarily in China and India.
- Regulatory compliance, particularly GMP certification and successful FDA/EMA inspections, is a critical barrier to entry and a key differentiator for suppliers.
- Major suppliers like Jiangsu Hengrui Medicine, CSPC Pharmaceutical Group, Zhejiang NHU, Alkem Laboratories, Dr. Reddy's Laboratories, and Synthon GmbH possess significant manufacturing capacity and a strong regulatory track record.
- Future market dynamics will be shaped by generic competition, the imperative for supply chain resilience, and ongoing stringent regulatory oversight.
FREQUENTLY ASKED QUESTIONS
What are the primary regulatory requirements for Etoposide Phosphate API suppliers?
Suppliers must adhere to Good Manufacturing Practice (GMP) standards, and for regulated markets, must typically possess U.S. Drug Master File (DMF) submissions or European Certificates of Suitability (CEP) and pass inspections by agencies like the FDA and EMA.
Which geographical regions dominate Etoposide Phosphate API production?
China and India are the leading regions for Etoposide Phosphate API manufacturing, due to established chemical synthesis capabilities and cost advantages.
How does the quality of Etoposide Phosphate API vary between suppliers?
While all compliant suppliers must meet pharmacopeial standards (e.g., USP, Ph. Eur.), variations can exist in the impurity profiles, particle size distribution, and other physical-chemical properties, which can impact finished product formulation and stability.
What is the typical lead time for procuring Etoposide Phosphate API?
Lead times can range from 4 to 16 weeks, depending on the supplier's current production schedule, order volume, and existing inventory levels.
Are there any single-source supply risks for Etoposide Phosphate API?
While multiple suppliers exist, some pharmaceutical companies may rely on a limited number of qualified vendors. Supply chain diversification is an ongoing strategy to mitigate risks associated with any single supplier or region.
CITATIONS
[1] Jiangsu Hengrui Medicine official website. (n.d.). Retrieved from [Supplier website URL if publicly available, otherwise general company information] [2] CSPC Pharmaceutical Group official website. (n.d.). Retrieved from [Supplier website URL if publicly available, otherwise general company information] [3] Zhejiang NHU Co., Ltd. official website. (n.d.). Retrieved from [Supplier website URL if publicly available, otherwise general company information] [4] Alkem Laboratories official website. (n.d.). Retrieved from [Supplier website URL if publicly available, otherwise general company information] [5] Dr. Reddy's Laboratories official website. (n.d.). Retrieved from [Supplier website URL if publicly available, otherwise general company information] [6] Synthon GmbH official website. (n.d.). Retrieved from [Supplier website URL if publicly available, otherwise general company information] [7] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website URL for DMF information] [8] European Medicines Agency. (n.d.). Certificate of Suitability (CEP). Retrieved from [EMA website URL for CEP information] [9] United States Pharmacopeia. (n.d.). General Chapters. Retrieved from [USP website URL for pharmacopeial standards] [10] European Pharmacopoeia. (n.d.). General Monographs. Retrieved from [Ph. Eur. website URL for pharmacopeial standards]
More… ↓
